Journal
METABOLIC BRAIN DISEASE
Volume 34, Issue 1, Pages 353-366Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11011-018-0346-8
Keywords
Nicotinamide adenine dinucleotide (NAD); Nicotinamide ribose (NR); Alzheimer's disease (AD); Cognition; Dementia; Neuroinflammation
Categories
Funding
- National Key R&D Program of China [2018YFA0507700]
- National Natural Sciences Foundation of China [81573400]
- Zhejiang Provincial Natural Science Foundation of China [LY18H170001]
- Public Technology Application Research of Zhejiang Province [2016F82G2010036]
Ask authors/readers for more resources
Nicotinamide adenine dinucleotide (NAD) supplementation to repair the disabled mitochondria is a promising strategy for the treatment of Alzheimer's disease (AD) and other dementia. Nicotinamide ribose (NR) is a safe NAD precursor with high oral bioavailability, and has beneficial effects on aging. Here, we applied NR supplied food (2.5g/kg food) to APP/PS1 transgenic AD model mice and aged mice for 3months. Cognitive function, locomotor activity and anxiety level were assessed by standard behavioral tests. The change of body weight, the activation of microglia and astrocytes, the accumulation of A and the level of serum nicotinamide phosphoribosyltransferase (NAMPT) were determined for the evaluation of pathological processes. We found that NR supplementation improved the short-term spatial memory of aged mice, and the contextual fear memory of AD mice. Moreover, NR supplementation inhibited the activation of astrocytes and the elevation of serum NAMPT of aged mice. For AD model mice, NR supplementation inhibited the accumulation of A and the migration of astrocyte to A. In addition, NR supplementation inhibit the body weight gain of aged and APP/PS1 mice. Thus, NR has selective benefits for both AD and aged mice, and the oral uptake of NR can be used to prevent the progression of dementia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available